Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. ($LRMR) announced an update on their ongoing clinical study. Larimar Therapeutics, Inc. is running an open-label Phase 2...

Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play

Larimar Therapeutics, Inc. ($LRMR) announced an update on their ongoing clinical study. Larimar Therapeutics, Inc. is running a Phase 3 study calle...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LRMR	$3.83	0.00%	391.89K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LRMR	$3.83	0%	391.89K
3
4
5
6

LRMR

Get Larimar Therapeutics, Inc. Data in Excel

Get Larimar Therapeutics, Inc. Data in Excel